Cyclopentolate Hydrochloride
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Cyclopentolate Hydrochloride
- Cyclopentolate Hydrochloride: Repurposing Evaluation — Insufficient Data to Complete Assessment
Cyclopentolate Hydrochloride: Repurposing Evaluation — Insufficient Data to Complete Assessment
One-Sentence Summary
Cyclopentolate Hydrochloride is a short-acting muscarinic antagonist classically used as an ophthalmic mydriatic and cycloplegic agent. The current Evidence Pack contains no TxGNN-predicted indications, and the Taiwan regulatory database returned zero approved products. A formal repurposing evaluation cannot be completed until the identified data gaps are resolved.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not resolved in current Evidence Pack |
| Predicted New Indication | No TxGNN predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — No actual studies available in this pack |
| Taiwan Market Status | Not marketed (0 authorizations found) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why a Prediction Cannot Yet Be Made
No TxGNN-predicted indications are present in this Evidence Pack, so no mechanistic bridge from an original to a new indication can be constructed at this time.
For background context: Cyclopentolate Hydrochloride is a competitive antagonist at muscarinic acetylcholine receptors (M1–M5). In ophthalmology it produces short-acting mydriasis and cycloplegia by blocking cholinergic input to the iris sphincter and ciliary muscle. It is structurally and pharmacologically related to atropine and tropicamide, and is routinely used during fundus examinations and in the management of anterior uveitis/iritis. An emerging area of interest is low-concentration cyclopentolate for paediatric myopia control, though this is not reflected in any TxGNN output here.
Critically, the Evidence Pack flags two unresolved data gaps that block further analysis:
- DG001 (Blocking): TFDA package insert warnings and contraindications have not been parsed into structured fields, preventing a safety screening.
- DG002 (High): Formal mechanism of action data from DrugBank was not populated despite the DrugBank query returning one result. This prevents mechanistic rationale generation.
Clinical Trial Evidence
Currently no related clinical trials are available in this Evidence Pack.
Literature Evidence
Currently no related literature is available in this Evidence Pack.
Taiwan Market Information
No regulatory authorizations were found for Cyclopentolate Hydrochloride in the TFDA product database queried on 2026-03-29 (result count: 0).
Note: The query log indicates the TFDA package insert source returned one result (
result_count: 1), but the parsed content was not forwarded into this Evidence Pack. This suggests a data pipeline gap rather than an absence of any regulatory document. Resolution of DG001 should recover this content.
Safety Considerations
Please refer to the package insert for safety information.
All safety fields in this Evidence Pack (key warnings, contraindications, drug–drug interactions) are either marked as data gaps or returned no results. No safety information can be reported until DG001 is resolved.
Conclusion and Next Steps
Decision: Hold
Rationale: This Evidence Pack lacks TxGNN predictions, mechanism of action data, safety information, and confirmed original indications — the minimum inputs required for any evidence-based repurposing assessment. Proceeding without these would produce an unreliable report.
To proceed, the following is needed:
- [DG001 — Blocking] Parse the TFDA package insert PDF already located (
result_count: 1) to extract structured warnings and contraindications - [DG002 — High] Retrieve and populate MOA and pharmacology fields from the DrugBank record already matched (
result_count: 1) - TxGNN pipeline re-run with verified drug identifier (DrugBank ID is currently null); confirm the canonical DrugBank ID for cyclopentolate (likely DB00979) and re-submit to the prediction pipeline
- Original indications field — populate from DrugBank or TFDA package insert once DG001/DG002 are resolved
- Once predictions are available, re-generate this report with a complete Evidence Pack (v5+)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.